RX.V - BioSyent Inc.
| Previous Close | 7.46 |
| Open | 7.47 |
| Bid | 7.35 x 0 |
| Ask | 7.66 x 0 |
| Day's Range | 7.35 - 7.47 |
| 52 Week Range | 6.24 - 8.30 |
| Volume | |
| Avg. Volume | 3,668 |
| Market Cap | 88.843M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 17.93 |
| EPS (TTM) | 0.41 |
| Earnings Date | Aug 21, 2023 - Aug 25, 2023 |
| Forward Dividend & Yield | 0.16 (2.17%) |
| Ex-Dividend Date | Jun 01, 2023 |
| 1y Target Est | 9.00 |
GlobeNewswireBioSyent Announces Approval of New Product
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has received regulatory approval from Health Canada for a new oncology supportive care product. BioSyent Pharma Inc. signed an exclusive Canadian Distribution Agreement for this product with a European partner in December 2022. “We are pleased to have received marketing approval for this new product, bringing it one st
- GlobeNewswire
BioSyent Releases Financial Results for Q1 2023
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2023. Key highlights include: First quarter (Q1) 2023 Canadian Pharmaceutical Net Revenues of $6,411,694 increased by 1% versus Q1 2022Q1 2023 International Pharmaceutical Net Revenues were $nil as compared to sales of $565,787 in Q1 2022Q1 2023 Total Company Net Revenues of $6,482,694 decreased by 8% versus Q1 2022Q1 2023 EB
- GlobeNewswire
BioSyent Declares Second Quarter 2023 Dividend
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for
- GlobeNewswire
BioSyent Schedules Q1 2023 Earnings Release for May 26, 2023
MISSISSAUGA, Ontario, May 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2023 on Friday, May 26, 2023 at 8:00am ET. A presentation on the Company’s first quarter 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioS
- GlobeNewswire
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians, Eight Years Running!
MISSISSAUGA, Ontario, May 02, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and physicians(1). This is the eighth consecutive year that FeraMAX® has been awarded this vote of confidence. The annual Survey on OTC Counselling and Recommendations is an important pharmaceutical industry indicator which tracks pharmacist and physician co
- GlobeNewswire
BioSyent to Present at 2023 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 18, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 25 and Wednesday, April 26, 2023 between 8:30am and 4:30pm ET. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s
- GlobeNewswire
BioSyent Announces Grant of Restricted Share Units
MISSISSAUGA, Ontario, March 31, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 72,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX
- GlobeNewswire
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2022
MISSISSAUGA, Ontario, March 21, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2022. Key highlights include: Fourth quarter (Q4) 2022 Total Company Net Revenues of $7,461,930 increased by 3% versus Q4 2021 Q4 2022 Total Company Net Revenues from continuing brands increased by 15% versus Q4 2021 (excluding brands discontinued at the end of 2021) Full year (FY) 2022 Total Company Net Reven
- GlobeNewswire
BioSyent Schedules Q4 and Full Year 2022 Earnings Release for March 21, 2023
MISSISSAUGA, Ontario, March 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2022 on Tuesday, March 21, 2023 after market close. A presentation on the Company’s fourth quarter and full year 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture E
GlobeNewswireBioSyent Announces Launch of New FeraMAX® Pd Maintenance 45
FeraMAX Pd Maintenance 45 FeraMAX Pd Maintenance 45 MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd Maintenance 45 is BioSyent’s third product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. The FeraMAX® Pd family of products con
- GlobeNewswire
BioSyent Declares First Quarter 2023 Dividend
MISSISSAUGA, Ontario, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share. This dividend qualifies as an 'eligible divide
- GlobeNewswire
BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care. The product has been marketed in Europe, USA and several other markets around the world to help cancer patients with certain side effects of their treatment. BioSyent anticipates launching the
- GlobeNewswire
BioSyent Announces Renewal of Normal Course Issuer Bid
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 690,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.70% of the Shares outstanding as of December 13, 2022. The NCIB will commence on De
- ACCESSWIRE
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022
The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.
- GlobeNewswire
BioSyent Releases Q3 and YTD 2022 Financial Results
MISSISSAUGA, Ontario, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022. Key highlights include: Third quarter (Q3) 2022 Total Company Net Revenues of $6,790,971 increased by 2% versus Q3 2021 Q3 2022 Total Company Net Revenues adjusted for discontinued brands increased by 9% versus Q3 2021 (excluding discontinued Aguettant System® and Cysview® brands) Year-to-date (YTD) 2022 T
- GlobeNewswire
BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022
MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2022 on Wednesday, November 16, 2022 after market hours. A presentation on the Company’s third quarter and first nine months 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Ve
- GlobeNewswire
BioSyent Initiates First Dividend
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2022, to shareholders of record at the close of business on November 30, 2022. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends re
- GlobeNewswire
BioSyent to Present at the Virtual MicroCap Leadership Summit
MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities. The MicroCap Leadership Summit is attended by retail and institutional investors from around the world. BioSye
- GlobeNewswire
BioSyent Announces Adoption of Dividend Policy
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors (the “Board”) today adopted a Dividend Policy in order to establish terms of reference for the Board in its decision-making around the declaration of any dividends to be issued to shareholders of the Company. “The adoption of a Dividend Policy by the Board is an important step in our evolution as a Company and a formal recognition o
- GlobeNewswire
BioSyent Releases Q2 and H1 2022 Financial Results
MISSISSAUGA, Ontario, Aug. 23, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2022. Key highlights include: Second quarter (Q2) 2022 Total Company Net Revenues of $6,634,875 decreased by 9% versus Q2 2021First half (H1) 2022 Total Company Net Revenues of $13,672,286 decreased by 7% versus H1 2021Q2 2022 Canadian Pharmaceutical Net Revenues from continuing brands of $6,272,185 increased by 1% ve
- GlobeNewswire
BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022
MISSISSAUGA, Ontario, Aug. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2022 on Tuesday, August 23, 2022 after market hours. A presentation on the Company’s second quarter and first half 2022 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange u
Simply Wall St.BioSyent (CVE:RX) shareholders have earned a 6.8% CAGR over the last three years
BioSyent Inc. ( CVE:RX ) shareholders might be concerned after seeing the share price drop 17% in the last quarter. In...